1. IL-33 in Rheumatic Diseases
- Author
-
Yuanji Dong, Jixin Zhong, and Lingli Dong
- Subjects
Medicine (General) ,Regulatory T cell ,business.industry ,Innate lymphoid cell ,autoimmune ,Inflammation ,Review ,General Medicine ,alarmin ,ST2 ,Mast cell ,Natural killer cell ,Interleukin 33 ,R5-920 ,medicine.anatomical_structure ,Immune system ,Immunology ,IL-33 ,medicine ,Medicine ,Macrophage ,medicine.symptom ,business ,rheumatic disease - Abstract
Interleukin-33 (IL-33) is a nuclear factor mainly expressed in barrier epithelium, endothelial cells, and fibroblast reticular cells. Some inflammatory cells also express IL-33 under certain conditions. The important role of IL-33 in allergic reactions, helminth infection, cancer, tissue fibrosis, chronic inflammation, organ transplantation, and rheumatic immune diseases has been extensively studied in recent years. IL-33 primarily activates various circulating and tissue-resident immune cells, including mast cell, group 2 innate lymphoid cell (ILC2), regulatory T cell (Treg), T helper 2 cell (Th2), natural killer cell (NK cell), and macrophage. Therefore, IL-33 plays an immunomodulatory role and shows pleiotropic activity in different immune microenvironments. The IL-33/serum stimulation-2 (ST2) axis has been shown to have a detrimental effect on rheumatoid arthritis, systemic lupus erythematosus, and other rheumatic diseases. Interestingly, IL-33 also plays a protective role in the repair of barrier epithelium and the activation of Tregs. Therefore, the role of IL-33/ST2 depends on the underlying pathological conditions in rheumatic diseases. This review focuses on the dual role of the IL-33/ST2 axis in rheumatic diseases.
- Published
- 2021
- Full Text
- View/download PDF